Fig. 1: CONSORT diagram of all participants who were assessed for eligibility for the trial, randomized to VR-CBTp + TAU or CBTp + TAU and followed up to 6 months posttreatment cessation.

Treatment cessation, mean = 4.5 months (95% confidence interval (CI) 4.3–4.6) after baseline; follow-up, mean = 10.5 months (95% CI 10.3–10.7) after baseline.